Dear Editor

We read with interest the study published by Pedersen and colleagues which reported that a genetic variant in the *IL6R* gene reduces the risk of the *JAK2*V617F somatic mutation and thus the risk to develop a myeloproliferative neoplasm [@bib0001]. They report that the variant rs4537545 is in high linkage disequilibrium with the *IL6R* variant rs2228145, which causes the non-synonymous exchange of Asp-358 to Ala-358 of the IL-6R protein [@bib0002], resulting in increased soluble IL-6R (sIL-6R) levels and reduced membrane-bound IL-6R due to increased proteolytic IL-6R cleavage [@bib0003].

While the finding is of high relevance and links an extracellular IL-6R variant with a mutation in an intracellular kinase by a so-far unknown mechanism, we would like to raise two important points to consider. First, the authors characterize the *IL6R* variant as anti-inflammatory due to reduced amounts of membrane-bound IL-6R on hepatocytes and thus diminished CRP production in homozygous carriers. While this is certainly true, we emphasize that increased sIL-6R in individuals in combination with soluble gp130 (sgp130) in the circulation acts as a natural buffer that can neutralize IL-6 \[[@bib0004],[@bib0005]\] and thereby reduce low-level inflammation, which is in line with the arguments put forward by Pedersen and colleagues [@bib0001].

Second, the authors compare these increased sIL-6R levels with patients under Tocilizumab treatment, which display even higher sIL-6R levels. In our opinion, these two scenarios cannot be compared, because Tocilizumab blocks all (s)IL-6R molecules in treated patients and renders them biologically inactive, while all (s)IL-6R molecules in individuals homozygous for rs2228145 are fully biologically active.
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